Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 14Recruiting 4Active not recruiting 4Unknown 2Withdrawn 1Terminated 1No longer available 1Available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

ruxolitinib 4venetoclax 1veliparib 1pevonedistat 1navitoclax 1givinostat hydrochloride 1givinostat 1fludarabine phosphate 1elotuzumab 1bomedemstat 1Whole-Body Irradiation 1Valganciclovir 1Topotecan 1Therapeutics 1Tacrolimus 1Sirolimus 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Hydroxyurea 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Etoposide 1Drug Evaluation 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Polycythemia Vera × ruxolitinib × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT05548062 2025-09-03

Prospero

Novartis

Active not recruiting
242 enrolled
Myeloid

Polycythemia Vera

NCT02577926 2025-06-10

Ruxo-BEAT

RWTH Aachen University

Phase 2 Active not recruiting
207 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡